Is Spyre Therapeutics (SYRE) One of the Small-Cap Stocks That Are On Fire Right Now? [Yahoo! Finance]
Spyre Therapeutics, Inc. (SYRE)
Company Research
Source: Yahoo! Finance
closed an underwritten public offering, generating ~$463.5 million in gross proceeds. The final total reflects the full exercise of the underwriters' option to purchase an additional 975,000 shares, bringing the total number of shares of common stock sold to 7,475,000 at a public offering price of $62.00 per share. The company plans to use these funds to further its development of long-acting antibodies and combination therapies targeting inflammatory bowel disease/IBD and rheumatic conditions. The offering was managed by a consortium of major financial institutions, with Jefferies LLC, Goldman Sachs & Co. LLC, Evercore ISI, and Guggenheim Securities acting as joint book-running managers. LifeSci Capital LLC served as a passive bookrunner. Is Spyre Therapeutics (SYRE) One of the Small-Cap Stocks That Are On Fire Right Now? 15 States with the Best Healthcare in the US The transaction was conducted under a registration statement that became effective in February, with the final pros
Show less
Read more
Impact Snapshot
Event Time:
SYRE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SYRE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SYRE alerts
High impacting Spyre Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SYRE
News
- Spyre Therapeutics (SYRE): Favorite Stock of Elite Money Managers [Yahoo! Finance]Yahoo! Finance
- Spyre Therapeutics (SYRE) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=SYRE&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "holMarketBeat
- Here's What Raymond James Says About Spyre Therapeutics Inc (SYRE) [Yahoo! Finance]Yahoo! Finance
- Spyre Therapeutics (SYRE) had its price target raised by JonesTrading from $64.00 to $95.00. They now have a "buy" rating on the stock.MarketBeat
- Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 MillionGlobeNewswire
SYRE
Earnings
- 11/4/25 - Beat
SYRE
Sec Filings
- 4/22/26 - Form SCHEDULE
- 4/20/26 - Form SCHEDULE
- 4/16/26 - Form 8-K
- SYRE's page on the SEC website